NASH Treatment Market Set for Rapid Growth as Rezdiffra and Wegovy Establish Fibrosis-Focused Pathways — STRATEGIC MARKET RESEARCH LLP

Event summary

The global NASH treatment market is projected to grow from $8.75 billion in 2025 to $46.87 billion by 2032, a CAGR of 27.1%.
Rezdiffra (Madrigal Pharmaceuticals) became the first FDA-approved therapy for NASH with noncirrhotic disease and moderate-to-advanced fibrosis in March 2024.
Wegovy (Novo Nordisk) received FDA approval for MASH with moderate-to-advanced fibrosis in August 2025, expanding treatment into obesity and diabetes care.
Approximately 6 million to 8 million Americans have NASH with moderate-to-advanced liver scarring, according to the FDA.

The big picture

The NASH treatment market is transitioning from a broad fatty liver focus to a fibrosis-confirmed prescription category, driven by the approval of Rezdiffra and Wegovy. This shift requires healthcare systems to develop diagnostic and referral pathways to identify high-risk patients. The market's rapid growth potential hinges on manufacturers' ability to navigate payer requirements and integrate treatments into existing metabolic-care networks.

What we're watching

Diagnostic Infrastructure: The pace at which healthcare systems adopt noninvasive fibrosis-staging tools will determine how quickly the commercial treatment pool expands.
Payer Dynamics: How payers structure prior authorization and coverage rules for NASH therapies will significantly impact prescription volumes and market share.
Competitive Landscape: Whether Rezdiffra can maintain its first-mover advantage against established metabolic-care drugs like Wegovy and emerging late-stage pipeline candidates.